Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 study of MD-352 in patients with dysmenorrhea
jRCT2011240049Phase 3Active, not recruiting
- Sponsor
- Mochida Pharmaceutical Co., Ltd.
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of MD-352 in dysmenorrhea (3 arms), sponsored by Mochida Pharmaceutical Co., Ltd. Primary endpoints: Change in dysmenorrhea score, Adverse events and 1 more. Started Dec 2024; status: active, not recruiting.
02
Drugs
MD-352
03
Conditions
dysmenorrhea
Beyond the preview
Go deeper on jRCT2011240049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011240049.